Is It Possible to Differentiate the Impact of Pediatric Monophasic Demyelinating Disorders and Multiple Sclerosis After a First Episode of Demyelination?

被引:0
|
作者
Aubert-Broche, Berengere [1 ]
Fonov, Vladimir [1 ]
Weier, Katrin [1 ]
Narayanan, Sridar [1 ]
Arnold, Douglas L. [1 ]
Banwell, Brenda [2 ,3 ]
Collins, D. Louis [1 ]
机构
[1] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada
[2] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada
[3] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
关键词
MRI; ATROPHY; AGE;
D O I
10.1007/978-3-319-14905-9_4
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
A first episode of acute demyelination of the central nervous system may be a monophasic transient illness or represent the first attack of multiple sclerosis (MS). This study investigates if it is possible to distinguish these two groups of patients retrospectively at the time of the first episode, in a pediatric population. For each patient, the method consists in fitting an individual brain growth curve using multiple follow-up time-points, and using this curve to predict 4 metrics at the first attack: brain volume, brain growth rate, thalamus volume normalized by the brain volume (called normalized thalamus) and normalized thalamus growth rate. These metrics were compared to age-and-sex matched healthy controls by computing z-scores. In this study, 85 patients were scanned up to 8 years after the first attack. During this follow-up period, 23 patients were subsequently diagnosed with MS (MS group). Among the 62 patients with a transient illness, 9 suffered from monophasic acute disseminated encephalomyelitis (ADEM group). The 53 remaining formed the non-ADEM monophasic (MONO) group. The normalized thalamus growth rate was the only metric that distinguished patient groups: the z-scores were significantly smaller for MS than for the MONO group (p<0.01). Whereas 93% of monophasic subjects were correctly classified with a linear discriminant analysis, only 13% of the MS subjects were correctly classified, due to a large inter-individual variability in this group.
引用
收藏
页码:38 / 48
页数:11
相关论文
共 50 条
  • [31] IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
    Kinkel, Revere P.
    Kollman, Craig
    NEUROLOGY, 2006, 67 (06) : 1104 - 1105
  • [32] Changes in employment status over time in multiple sclerosis following a first episode of central nervous system demyelination, a Markov multistate model study
    Zarghami, Amin
    Fuh-Ngwa, Valery B.
    Claflin, Suzi
    van Der Mei, Ingrid
    Ponsonby, Anne-Louise
    Broadley, Simon
    Simpson-Yap, Steve V.
    Taylor, Bruce
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (01)
  • [33] The 'mirror' pattern in the diagnostic work-up after the first demyelinating event can be associated with multiple sclerosis
    Sicchieri, Monica
    Marastoni, Damiano
    Mmarini, Maddalena
    Acartezzini, Arianna
    Lippi, Giuseppe
    Bonetti, Bruno
    Calabrese, Massimiliano
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 398 - 399
  • [34] Application of the 2017 McDonald criteria for the diagnosis of Multiple Sclerosis after a first demyelinating event in patients from Argentina
    Pagani Cassara, F.
    Curbelo, M. C.
    Vazquez, G.
    Sedeno, L.
    Steinberg, J.
    Carra, A.
    Sinay, V.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 166 - 167
  • [35] Serum neurofilament light chain as a predictive marker in patients after first demyelinating event suggestive of multiple sclerosis
    Benova, B.
    Barro, C.
    Andelova, M.
    Uher, T.
    Michalak, Z.
    Tyblova, M.
    Kucerova, K.
    Hrnciarova, T.
    Vaneckova, M.
    Kadrnozkova, L.
    Motyl, J.
    Havrdova, E.
    Kuhle, J.
    Horakova, D.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 450 - 450
  • [36] Prognostic relevance of antimyelin antibodies for the progression to multiple sclerosis after a first demyelinating event: Results of the BENEFIT trial
    Kuhle, J.
    Mehling, M.
    Hartung, H. -P.
    Freedman, M. S.
    Polman, C. H.
    Edan, G.
    Miller, D. H.
    Montalban, X.
    Bauer, L.
    Dahms, S.
    Pohl, C.
    Sandbrink, R.
    Lindberg, R.
    Kappos, L.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 55 - 55
  • [37] IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event
    Kinkel, RP
    Kollman, C
    O'Connor, P
    Murray, TJ
    Simon, J
    Arnold, D
    Bakshi, R
    Weinstock-Gutman, B
    Brod, S
    Cooper, J
    Duquette, P
    Eggenberger, E
    Felton, W
    Fox, R
    Freedman, M
    Galetta, S
    Goodman, A
    Guarnaccia, J
    Hashimoto, S
    Horowitz, S
    Javerbaum, J
    Kasper, L
    Kaufman, M
    Kerson, L
    Mass, M
    Murray, TJ
    O'Connor, P
    Rammohan, K
    Reiss, M
    Rolak, L
    Rose, J
    Scott, T
    Selhorst, J
    Shin, R
    Smith, C
    Stuart, W
    Thurston, S
    Wall, M
    NEUROLOGY, 2006, 66 (05) : 678 - 684
  • [38] Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina
    Cassara, Fatima Pagani
    Curbelo, Maria Celeste
    Vazquez, Guido
    Sedeno, Lucas
    Steinberg, Judith
    Carra, Adriana
    Sinay, Vladimiro J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 41
  • [39] Combined VEP and OCT after optic neuritis can differentiate neuromyelitis optica spectrum disorders from multiple sclerosis
    Leocani, L.
    Vabanesi, M.
    Vitali, F.
    Pisa, M.
    Guerrieri, S.
    Di Maggio, G.
    Moiola, L.
    Rodegher, M.
    Radaelli, M.
    Medaglini, S.
    Del Carro, U.
    Martinelli, V.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 806 - 807
  • [40] Predictive factors of multiple sclerosis relapse after the first demyelinating event: A 5-year follow-up
    Kolcava, Jan
    Pelisek, Ondrej
    Vlckova, Eva
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 71